6272 related articles for article (PubMed ID: 3498854)
21. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
22. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
Wawrzynczak EJ; Derbyshire EJ; Henry RV; Parnell GD; Smith A; Waibel R; Stahel RA
Br J Cancer Suppl; 1991 Jun; 14():71-3. PubMed ID: 1645577
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber.
Goldmacher VS; Blättler WA; Lambert JM; McIntyre G; Stewart J
Mol Pharmacol; 1989 Nov; 36(5):818-22. PubMed ID: 2531272
[TBL] [Abstract][Full Text] [Related]
25. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
27. Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment.
Colombatti M; Dell'Arciprete L; Chignola R; Tridente G
Cancer Res; 1990 Mar; 50(5):1385-91. PubMed ID: 2302703
[TBL] [Abstract][Full Text] [Related]
28. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
29. [Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity].
Zhao C
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):109-11. PubMed ID: 1618077
[TBL] [Abstract][Full Text] [Related]
30. [Selective cytotoxic effect of an immunotoxin on human erythroid tumor cells].
Tonevitskiĭ AG; Agapov II; Mechetner EB
Mol Biol (Mosk); 1991; 25(5):1181-7. PubMed ID: 1753950
[TBL] [Abstract][Full Text] [Related]
31. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Jan; 44(1):201-8. PubMed ID: 6140077
[TBL] [Abstract][Full Text] [Related]
33. An immunotoxin cytotoxic for breast cancer cells in vitro.
LeMaistre CF; Edwards DP; Krolick KA; McGuire WL
Cancer Res; 1987 Feb; 47(3):730-4. PubMed ID: 3492266
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of anti-carcinoembryonic antigen immunotoxin cytotoxicity by monoclonal antibodies reacting with co-expressed carcinoembryonic antigen epitopes.
Byers VS; Pawluczyk I; Berry N; Durrant L; Robins RA; Garnett MC; Price MR; Baldwin RW
J Immunol; 1988 Jun; 140(11):4050-5. PubMed ID: 2453564
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
36. Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line.
Tejuca M; Díaz I; Figueredo R; Roque L; Pazos F; Martínez D; Iznaga-Escobar N; Pérez R; Alvarez C; Lanio ME
Int Immunopharmacol; 2004 Jun; 4(6):731-44. PubMed ID: 15135315
[TBL] [Abstract][Full Text] [Related]
37. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.
Till M; May RD; Uhr JW; Thorpe PE; Vitetta ES
Cancer Res; 1988 Mar; 48(5):1119-23. PubMed ID: 3257712
[TBL] [Abstract][Full Text] [Related]
38. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
[TBL] [Abstract][Full Text] [Related]
39. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
40. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
Carcenac M; Larroque C; Langlois R; van Lier JE; Artus JC; Pèlegrin A
Photochem Photobiol; 1999 Dec; 70(6):930-6. PubMed ID: 10628305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
